CAJ | 학술논문

目的探讨全血中miR-155与乳腺癌临床病理特征之间的关系.方法收集2010年12月至2011年4月淮安市第一人民医院甲状腺乳腺外科符合入选条件的65例女性(乳腺癌47例,非乳腺癌18例)的血液标本,提取全血中总RNA,通过荧光实时定量PCR的方法,检测全血中miR-155表达水平,分析其与乳腺癌临床病理特征间的关系.结果乳腺癌患者全血中的miR-155的表达水平与非乳腺癌患者相比上调,差异有统计学意义(P＜0.05)；与淋巴结转移阴性的乳腺癌患者相比,淋巴结转移阳性的乳腺癌患者全血中miR-155的表达水平上调,差异有统计学意义(P＜0.05)；与Ⅰ、Ⅱ期乳腺癌患者相比,Ⅲ期乳腺癌患者全血中miR-155的表达水平上调,差异有统计学意义(P＜0.05)；与T1乳腺癌相比,T2和T3乳腺癌患者中miR-155表达上调,差异有统计学意义(P＜0.05)；与ER、PR阴性的乳腺癌相比,ER、PR阳性的患者全血中miR-155表达水平下调,差异有统计学意义(P＜0.05).结论全血中miR-155的表达水平与乳腺癌的临床病理特征相关,全血中的miRNA有望成为新一代的乳腺癌的肿瘤标志物.
목적 탐토전혈중miR-155여유선암림상병리특정지간적관계.방법 수집2010년12월지2011년4월회안시제일인민의원갑상선유선외과부합입선조건적65례녀성(유선암47례,비유선암18례)적혈액표본,제취전혈중총RNA,통과형광실시정량PCR적방법,검측전혈중miR-155표체수평,분석기여유선암림상병리특정간적관계.결과 유선암환자전혈중적miR-155적표체수평여비유선암환자상비상조,차이유통계학의의(P＜0.05)；여림파결전이음성적유선암환자상비,림파결전이양성적유선암환자전혈중miR-155적표체수평상조,차이유통계학의의(P＜0.05)；여Ⅰ、Ⅱ기유선암환자상비,Ⅲ기유선암환자전혈중miR-155적표체수평상조,차이유통계학의의(P＜0.05)；여T1유선암상비,T2화T3유선암환자중miR-155표체상조,차이유통계학의의(P＜0.05)；여ER、PR음성적유선암상비,ER、PR양성적환자전혈중miR-155표체수평하조,차이유통계학의의(P＜0.05).결론 전혈중miR-155적표체수평여유선암적림상병리특정상관,전혈중적miRNA유망성위신일대적유선암적종류표지물.
Objective To investigate the expression of miR-155 in whole blood of patients with breast cancer and explore the possibility of miR-155 in whole blood as a marker of beast cancer. Methods 65 cases (breast cancer:47 cases, non-breast cancer:18 cases) in Thyroid and Breast Surgery Department of No.1 People's Hospital of Huai'an from Dec 2010 to Apr 2011 were enrolled according to the selected criteria.Two milliliters anticoagulant blood were sampled to isolate total RNA.The expression level of miR-155 in whole blood was measured by real-time quantitative polymerase chain reaction (real-time qPCR)analysis.The relationship between the expression level of miR-155 in whole blood and the clinical pathological fearutres was analyzed.Results The expression level of miR-155 in breast cancer patients was up-regulated compared with that in non-breast cancer patients(P ＜ 0.05).The expression level of miR-155 in patients with positive lymph nodes was up-regulated compared with that in patients with negative lymph nodes( P ＜ 0.05).The expression level of miR-155 in stage Ⅲ breast cancer was up-regulated compared with that in stage Ⅰ & Ⅱ breast cancer( P ＜ 0.05 ).The expression level of miR-155 in patients with positive ER and PR was down-regulated compared with that in patients with negative ER and PR breast cancer.Conclusion The study demonstrates that the expression of miR-155 in whole blood is related to clinical pathological features of patients with breast cancer and can be used as a potential marker of breast cancer.